Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | PRO1160 |
| Synonyms | |
| Therapy Description |
PRO1160 is an antibody-drug conjugate (ADC) comprising an anti-CD70 monoclonal antibody linked to exatecan, which potentially inhibits tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 1759). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| PRO1160 | PRO-1160|PRO 1160 | CD70 Antibody 6 | PRO1160 is an antibody-drug conjugate (ADC) comprising an anti-CD70 monoclonal antibody linked to exatecan, which potentially inhibits tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 1759). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05721222 | Phase Ib/II | PRO1160 | Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001) | Terminated | USA | 1 |